Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PORCN | Q9H237 | 2/20 | 1.00 |
| ▸ | WNT3A | P56704 | 15/20 | 0.81 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.67 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.67 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.67 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.67 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.67 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724609 | 1.00 | PORCN (1.00) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL1723593 | 0.90 | WNT3A (1.00) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL2182327 | 0.90 | WNT3A (1.00) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL1723832 | 0.89 | WNT3A (1.00) | PORCNWNT3A | |
| SCHEMBL2454059 | 0.86 | WNT3A (1.00) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL27971532 | 0.86 | WNT3A (0.93) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL2182842 | 0.86 | WNT3A (0.93) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL2184335 | 0.84 | WNT3A (0.80) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL2184404 | 0.84 | WNT3A (0.80) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL1492885 | 0.83 | PORCN (0.71) | PORCNWNT3APSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 723 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122038285-A | Kit and method for constructing human bone organ by using pluripotent stem cells | 广东医科大学附属医院 | 2026-05-15 | — | — | CN | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| US-12570956-B2 | Efficient derivation of stable pluripotent bovine embryonic stem cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-10 | — | — | US | claimed |
| US-20260022347-A1 | TREATMENT AGENT FOR LUNG ADENOCARCINOMAS | UNIV KEIO (JP) | 2026-01-22 | — | — | US | claimed |
| EP-4346928-B1 | BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS | US HEALTH (US) | 2026-01-14 | — | — | EP | claimed |
| US-20260002121-A1 | IMPROVED METHODS OF PREPARING DIFFERENT MESODERM CELL TYPES | CHILDRENS HOSPITAL MED CT (US) | 2026-01-01 | — | — | US | claimed |
| WO-2025262235-A1 | UNGULATE PLURIPOTENT STEM CELL CULTURE MEDIUM | MEAT TOMORROW APS (DK) | 2025-12-26 | — | — | WO | claimed |
| US-12503685-B2 | Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-12-23 | — | — | US | claimed |
| US-12485147-B2 | Method for producing cell mass including pituitary tissue, and cell mass thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2025-12-02 | — | — | US | claimed |
| US-12486495-B2 | Cardiac organoid, manufacturing method therefor, and method for evaluating drug toxicity by using same | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2025-12-02 | — | — | US | claimed |
| CN-114438037-A | Method for preparing inductive mesenchymal stem cells | 深圳市乐土生物医药有限公司 | 2022-05-06 | — | — | CN | claimed |
| WO-2022051847-A9 | METHODS FOR GENERATING NEURAL PROGENITOR CELLS WITH A SPINAL CORD IDENTITY | UNIVERSITY HEALTH NETWORK (CA) | 2022-04-21 | — | — | WO | claimed |
| CN-114369577-A | Cattle induced expansion pluripotent adult stem cell, line establishing method and culture solution | 内蒙古大学 | 2022-04-19 | — | — | CN | claimed |
| CN-114369567-A | Method for establishing bovine expanded pluripotent embryonic stem cells and culture solution | 内蒙古大学 | 2022-04-19 | — | — | CN | claimed |
| WO-2022031952-A9 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022063224-A1 | ACTIVATED PLURIPOTENT STEM CELL, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院动物研究所 | 2022-03-31 | — | — | WO | claimed |
| CN-114250195-A | Activated pluripotent stem cell and preparation method and application thereof | 中国科学院动物研究所 | 2022-03-29 | — | — | CN | claimed |
| WO-2022051847-A1 | METHODS FOR GENERATING NEURAL PROGENITOR CELLS WITH A SPINAL CORD IDENTITY | UNIVERSITY HEALTH NETWORK (CA) | 2022-03-17 | — | — | WO | claimed |
| WO-2022031952-A2 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-02-10 | — | — | WO | claimed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022347-A1 | TREATMENT AGENT FOR LUNG ADENOCARCINOMAS | AXIN2, CTNND1, WNT1 | PORCN 452/4885WNT3A 5/4885PSEN1 3911/4885 |
| US-20260002121-A1 | IMPROVED METHODS OF PREPARING DIFFERENT MESODERM CELL TYPES | BMP4, RARB, WNT3A | PORCN 3877/4885WNT3A 3/4885PSEN1 4035/4885 |
| US-12570956-B2 | Efficient derivation of stable pluripotent bovine embryonic stem cells | WNT1, PHKA1, ACVR1 | PORCN 4724/4885WNT3A 5/4885PSEN1 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.